Dermaroller and Topical Application
Published in
Evaluation of efficacy of derma roller sizes vs topical application for administration of QR678® anti-hair loss formulation in the clinical assessment of androgenetic alopecia
- Background and Scientific Context
In clinical dermatology practice, multiple delivery methods are used to support scalp-based formulations, particularly in the context of androgenetic alopecia. Topical application remains the most commonly used approach due to ease of use and patient familiarity. Dermaroller-assisted delivery, which involves controlled micro-injury to the scalp, has also been explored as a method to enhance localized scalp exposure and procedural penetration.
Comparative documentation of different delivery techniques provides insight into procedural considerations, tolerability, and observable hair and scalp parameters under routine practice conditions. This study presents descriptive clinical documentation of patients with androgenetic alopecia receiving QR678 through two different delivery approaches—dermaroller-assisted application and topical application—without attributing causality or clinical outcomes to either method.
- Study Design and Methodology
One group received QR678 administered using a dermaroller-assisted technique, involving controlled microneedling of the scalp followed by localized application. The second group received QR678 via topical application according to a standardized protocol. All procedures were performed under dermatological supervision. The study followed an open-label design without randomization, blinding, or placebo control. Baseline assessments were conducted prior to initiation of either delivery approach, with follow-up evaluations performed at scheduled intervals over the observation period. The objective of the study was to document hair and scalp parameters observed during use of two different delivery techniques in routine clinical practice.
- Assessment Parameters
- Hair pull testing to record active hair shedding at the time of examination
- Trichoscopic and videomicroscopic evaluation to document hair density, follicular distribution, and hair shaft characteristics
- Global photographic assessment to visually record scalp appearance across defined regions
- Patient-reported observations recorded during structured clinical consultations
- Observational Findings
Trichoscopic and photographic documentation provided visual records of hair and scalp parameters over time within individual patients. Variability in observations was noted across participants, reflecting known differences in hair cycle phases, scalp characteristics, and individual biological response. Patient-reported observations reflected subjective perceptions related to hair appearance, scalp feel, and procedural experience. These reports were documented descriptively and were not interpreted as indicators of clinical benefit or comparative outcome.
- Procedural and Tolerability Observations
Procedural tolerability was monitored throughout the study duration. In the dermaroller-assisted group, observations included transient scalp sensations associated with microneedling. In the topical application group, observations were limited to localized scalp sensations associated with application.
Across both groups, reported observations were mild and temporary. No systemic adverse events were reported during the observation period. No participants discontinued the study due to tolerability-related concerns.
Procedural differences between dermaroller-assisted and topical application were documented as part of routine clinical observation, without interpretation regarding preference, effectiveness, or long-term impact.
- Scope, Limitations, and Research Relevance
The study is subject to limitations inherent to observational clinical evaluations, including absence of randomization, lack of blinding, and reliance on descriptive documentation. The study does not establish therapeutic efficacy, comparative advantage, or long-term outcomes associated with either delivery approach.
Within these constraints, the paper contributes structured clinical documentation of hair and scalp parameters observed with two different methods of QR678 administration. The findings may serve as reference material for clinicians reviewing procedural considerations and delivery approaches under routine dermatology practice conditions.
- Disclaimer
QR678® is marketed as a cosmetic formulation in many countries and does not claim to diagnose, treat, cure, prevent, restore, or regrow hair. The research papers and clinical articles referenced on this website are peer-reviewed scientific publications authored by qualified medical professionals and represent the observations and conclusions of the respective authors, based on their individual clinical research.
These clinical references are provided for informational and educational purposes and should not be interpreted as promotional claims or outcome guarantees by or QR678®. Consumers are advised to consult a qualified healthcare professional for medical interpretation or hair- or scalp-related concerns.
